Business Context and Reporting Period
Company: Ginkgo Bioworks Holdings, Inc. (NYSE: DNA)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2024
Business Overview: Ginkgo operates two primary segments: Cell Engineering, providing biological R&D services and tools (Foundry and Codebase) across pharmaceuticals, agriculture, and industrial biotechnology; and Biosecurity, offering biomonitoring (Canopy) and digital surveillance (Horizon) services to government and commercial customers to detect biological threats. The company does not manufacture end products but enables customers to engineer biology.
Key Financial Metrics
| Metric (in millions) | 2024 | 2023 |
|---|---|---|
| Total Revenue | $227.0 | $251.5 |
| Net Loss | $(547.0) | $(892.9) |
| Operating Loss | $(559.8) | $(864.4) |
| Adjusted EBITDA | $(293.3) | $(365.0) |
| Cash and Cash Equivalents (Year End) | $561.6 | $944.1 |
| Net Cash Used in Operating Activities | $(319.6) | $(295.5) |
| Accumulated Deficit | $(5.8 billion) | $(5.3 billion) |
Revenue Breakdown: Cell Engineering revenue increased to $174.0 million (up $30.4 million), while Biosecurity revenue declined to $53.1 million (down $54.9 million) due to the cessation of COVID-19 school testing services.
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased 9.7% year-over-year, driven primarily by the end of high-volume COVID-19 product revenue in the Biosecurity segment, partially offset by growth in Cell Engineering.
- Improved Loss Profile: Net loss improved by $345.8 million compared to 2023, largely due to significant cost reductions from restructuring and the deconsolidation of Zymergen.
- Restructuring: The company initiated a restructuring plan in Q2 2024, reducing the workforce by over 40% and consolidating facilities. This resulted in $24.2 million in restructuring charges for 2024.
- Impairments: Recorded a full goodwill impairment of $47.9 million related to the Cell Engineering reporting unit and $5.8 million in lab equipment impairments.
- Non-Cash Revenue: Recognized $45.4 million in non-cash revenue from the termination of the Motif FoodWorks contract, which accelerated the recognition of previously deferred revenue.
Guidance, Outlook, and Risks
Management Outlook: Management expects operating expenses to remain consistent or decline in 2025 compared to 2024, reflecting the stabilization of operational overhead and the impact of restructuring. The company believes its current cash position ($561.6 million) is sufficient to fund operations for at least the next 12 months.
Strategic Shifts:
- Biosecurity: Transitioning from pandemic-era testing to scalable global surveillance infrastructure (Canopy and Horizon) with recurring revenue models.
- Cell Engineering: Launching new "tools" offerings (Datapoints, AI Model API, lab automation) to complement end-to-end solutions. Commercial terms for new contracts have shifted to remove downstream value share (equity/milestones) in favor of upfront fees.
Key Risks and Contingencies:
- Liquidity: History of net losses and negative cash flow; may require additional capital in the future.
- Customer Concentration: Three customers accounted for 49% of total revenue in 2024.
- Restructuring Execution: Risks that cost savings may not materialize as anticipated or that facility subleasing may be delayed.
- Equity Investments: Exposure to volatility and liquidity risks from holding equity interests in customers and partners.
- Regulatory: Subject to complex regulations regarding GMOs, controlled substances (DEA), and data privacy (HIPAA/GDPR).
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $561.6 million cash balance against the projected burn rate, considering the $279.3 million remaining commitment to Google Cloud and $29.6 million to Twist Bioscience.
- Revenue Quality: Assess the sustainability of the $45.4 million non-cash revenue spike from the Motif contract termination and the transition to cash-based revenue models in new contracts.
- Restructuring Costs: Monitor the realization of the estimated $20.0–$23.0 million in workforce reduction costs and the timeline for facility subleasing to confirm expense stabilization in 2025.
- Biosecurity Pivot: Evaluate the growth trajectory of the new Canopy and Horizon services to replace the lost COVID-19 revenue stream.
- Customer Concentration: Review the dependency on the top three customers (49% of revenue) and the risk of contract non-renewal.